Eric M Ruderman

10PUBLICATIONS
47CO-AUTHORS
Molecular targetsRheumatology and arthritisToxicology (incl. clinical toxicology)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 20, 2026
Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.

|May 01, 2023
Integrating PROMIS Measures in a Treat-to-Target Approach to Standardize Patient-Centered Treatment of Rheumatoid Arthritis.

George J Greene, Jennifer L Beaumont, Emily J Bacalao

|Oct 15, 2022
Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.

Ying-Ying Leung, Tatiana V Korotaeva, Liliana Candia

|Dec 28, 2021
Evaluation of an Intervention to Support Patient-Rheumatologist Conversations About Escalating Treatment in Patients with Rheumatoid Arthritis: A Proof-of-Principle Study.

Maria I Danila, Lang Chen, Eric M Ruderman

|Sep 06, 2021
Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis.

Laura C Arneson, Kristen J Carroll, Eric M Ruderman

|Apr 03, 2020
The Quality of Randomized Controlled Trials in High-impact Rheumatology Journals, 1998-2018.

Michael S Putman, Ashley Harrison Ragle, Eric M Ruderman

Pageof 2

Frequent Collaborators

3 joint publications

Michael S Putman

2 joint publications

Jeffrey A Sparks

1 joint publications

Laura C Arneson

1 joint publications

Kristen J Carroll